Portfolio News
Sofinnova Digital Medicine
Ashley Lakner, PhD Joins Cure51 as Chief Scientific Officer (CSO)!
We’re thrilled to welcome Ashley Lakner, PhD, our new Chief Scientific Officer (CSO)!
Ashley joins our team with an exceptional track record in oncology drug discovery and precision medicine. Most recently leading Oncology Discovery at Roche pRED, and previously as VP of Precision Molecular Oncology at Bayer, Ashley advanced multiple molecules across key modalities into early clinical development through rigorous translational research.
Ashley brings deep scientific expertise, extensive drug discovery experience and proven leadership of multidisciplinary teams, helping us advance our mission of turning breakthrough biology into meaningful patient impact.
Welcome to the team!
Related News
Abivax announces full year 2025 financial results and provides business updates
Sensorion reports six-month update from the Audiogene Phase 1/2 Trial of SENS-501 and advances GJB2-GT (SENS-601) toward first-in-human clinical development
Elevara Medicines doses first patient in Phase 2b START-SYNERGY trial of ELV001 in rheumatoid arthritis patients with incomplete response to TNFi
May Health raises $11.7M to advance its novel technology to treat PCOS-related infertility
Adapt or go extinct: Novameat unveils the ingredient that will save the global meat crisis